Xenon Pharmaceuticals (XENE) Misses Q2 EPS by 5c

Xenon Pharmaceuticals (NASDAQ: XENE) reported Q2 EPS of ($0.75), $0.05 worse than the analyst estimate of ($0.70).

For earnings history and earnings-related data on Xenon Pharmaceuticals (XENE) click here.

You May Also Be Interested In

• Calumet Specialty Products Partners (CLMT) PT Raised to $47 at UBS
• Vivakor raises 2026 supply and trading outlook to $3.5 billion
• Leidos wins $56M Navy behavioral health research contract